Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3

By sjmartinez • December 5, 2022

Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. Breast. 2022 Nov 15;66:324-331. doi: 10.1016/j.breast.2022.11.005. Epub ahead of print. PMID: 36463643.

Tags: Advanced breast cancer, chemotherapy, Digestive Diseases, Hematology/Oncology, Palbociclib, Progression-free survival, Publications, safety

Diet and the gut microbiome in patients with Parkinson’s disease

Kwon D, Zhang K, Paul KC, Folle AD, Del Rosario I, Jacobs JP, Keener AM, Bronstein JM, Ritz B. Diet and the gut microbiome in[...]

Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota

Andréasson K, Olofsson T, Lagishetty V, Alrawi Z, Klaassens E, Holster S, Hesselstrand R, Jacobs JP, Wallman JK, Volkmann ER. Treatment for Rheumatoid Arthritis Associated[...]

Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block

Lee YT, Tseng HR, Yang JD. Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block. Hepatology. 2024 Apr 19.[...]